{"title":"Gd(3+)-DTPA-Meglumine-Anionic Linear Globular Dendrimer G1: Novel Nanosized Low Toxic Tumor Molecular MR Imaging Agent.","authors":"Tahmineh Darvish Mohamadi, Massoud Amanlou, Negar Ghalandarlaki, Bita Mehravi, Mehdi Shafiee Ardestani, Parichehr Yaghmaei","doi":"10.1155/2013/378452","DOIUrl":"https://doi.org/10.1155/2013/378452","url":null,"abstract":"<p><p>Despite the great efforts in the areas of early diagnosis and treatment of cancer, this disease continues to grow and is still a global killer. Cancer treatment efficiency is relatively high in the early stages of the disease. Therefore, early diagnosis is a key factor in cancer treatment. Among the various diagnostic methods, molecular imaging is one of the fastest and safest ones. Because of its unique characteristics, magnetic resonance imaging has a special position in most researches. To increase the contrast of MR images, many pharmaceuticals have been known and used so far. Gadopentetate (with commercial name Magnevist) is the first magnetic resonance imaging contrast media that has been approved by the US Food and Drug Administration. In this study, gadopentetate was first synthesized and then attached to a tree-like polymer called dendrimer which is formed by polyethylene glycol core and surrounding citric acid groups. Stability studies of the drug were carried out to ensure proper synthesis. Then, the uptake of the drug into liver hepatocellular cell line and the drug cytotoxicity were evaluated. Finally, in vitro and in vivo MR imaging were performed with the new synthetic drug. Based on the findings of this research, connecting gadopentetate to dendrimer surface produces a stronger, safer, and more efficient contrast media. Gd(III)-diethylenetriamine pentaacetate-meglumine-dendrimer drug has the ability to enter cells and does not produce significant cytotoxicity. It also increases the relaxivity of tissue and enhances the MR images contrast. The obtained results confirm the hypothesis that the binding of gadopentetate to citric acid dendrimer produces a new, biodegradable, stable, and strong version of the old contrast media.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":" ","pages":"378452"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/378452","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40230016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2013-01-01Epub Date: 2013-01-27DOI: 10.1155/2013/752471
Ganesh B Patil, Saurabh S Singh, Ketan P Ramani, Vivekanand K Chatap, Prashant K Deshmukh
{"title":"Design and development of novel dual-compartment capsule for improved gastroretention.","authors":"Ganesh B Patil, Saurabh S Singh, Ketan P Ramani, Vivekanand K Chatap, Prashant K Deshmukh","doi":"10.1155/2013/752471","DOIUrl":"https://doi.org/10.1155/2013/752471","url":null,"abstract":"<p><p>The aim of the proposed research work was to develop a novel dual-compartment capsule (NDCC) with polymeric disc for gastroretentive dosage form, which will ultimately result in better solubility and bioavailability of Ofloxacin. Floating ring caps were formulated by using different natural polymers, separating ring band and swellable polymer located at the bottom of capsule. Formulated ring caps were assessed for coating thickness, In vitro buoyancy, In vitro drug release, release kinetics and stability studies. Coating attained by the capsule shell was found to be 0.0643 mm. Depending on nature of natural polymer used, most of the formulations showed buoyancy for more than 9 hrs. Developed formulation demonstrated considerably higher drug release up to 9 hrs. The developed formulation F(E2) depicted the drug release according to Korsmeyer-Peppas model. There was not any significant change in performance characteristics of developed ring caps after subjecting them to stability studies. The present study suggests that the use of NDCC for oral delivery of Ofloxacin could be an alternative to improve its systemic availability which could be regulated by the floating approach. The designed dosage system can have futuristic applications over payloads which require stomach-specific delivery.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2013 ","pages":"752471"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/752471","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31257599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2013-01-01Epub Date: 2013-03-06DOI: 10.1155/2013/818364
Hideto Isogai, Noriaki Hirayama
{"title":"In Silico Prediction of Interactions between Site II on Human Serum Albumin and Profen Drugs.","authors":"Hideto Isogai, Noriaki Hirayama","doi":"10.1155/2013/818364","DOIUrl":"https://doi.org/10.1155/2013/818364","url":null,"abstract":"<p><p>Since binding of a drug molecule to human serum albumin (HSA) significantly affects the pharmacokinetics of the drug, it is highly desirable to predict the binding affinity of the drug. Profen drugs are a widely used class of nonsteroidal anti-inflammatory drugs and it has been reported that several members of the profen class specifically bind to one of the main binding sites named site II. The actual binding mode of only ibuprofen has been directly confirmed by X-ray crystallography. Therefore, it is of interest whether other profen drugs are site II binders. Docking simulations using multiple template structures of HSA from three crystal structures of complexes between drugs and HSA have demonstrated that most of the currently available profen drugs should be site II binders.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":" ","pages":"818364"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/818364","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40229904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cytological aspects on the effects of a nasal spray consisting of standardized extract of citrus lemon and essential oils in allergic rhinopathy.","authors":"Lydia Ferrara, Daniele Naviglio, Arturo Armone Caruso","doi":"10.5402/2012/404606","DOIUrl":"https://doi.org/10.5402/2012/404606","url":null,"abstract":"<p><p>In this paper, a new formulation of nasal spray was set up based on the extract of lemon pulp, obtained by using a new solid-liquid technology of extraction, added to pure Aloe juice, soluble propoli, and essential oils of Ravensara and Niaouly. It was tested in a clinical study in which 100 subjects were recruited for a period of one month. Nasal scraping was used for collecting samples and after the application of the May-Grünwald Giemsa standard technique, glass slides were analysed by using optical microscope with a 1000x oil immersion. A control group constituted of ten people was recruited as control and this group was administered with physiological solution (saline solution). The comparison of results obtained before and after the application of nasal spray showed a total reduction of eosinophils granulocytes and mast cells; clinical data were confirmed by improvement of clinical pictures of patients. The lemon-based nasal spray was a good alternative to conventional medicine for the treatment of perennial and seasonal allergic and vasomotor rhinopathy.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"404606"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/404606","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ondansetron HCl Microemulsions for Transdermal Delivery: Formulation and In Vitro Skin Permeation.","authors":"Jadupati Malakar, Amit Kumar Nayak, Aalok Basu","doi":"10.5402/2012/428396","DOIUrl":"https://doi.org/10.5402/2012/428396","url":null,"abstract":"<p><p>Ondansetron HCl delivery through oral route suffers due to its low bioavailability due to first-pass metabolism. Therefore, the microemulsion-based transdermal delivery may be a better substitute for it. The pseudoternary phase diagrams were constructed to determine compositions of microemulsions, and ondansetron HCl microemulsions for transdermal delivery were developed using isopropyl myristate or oleic acid as the oil phase, Tween 80 as the surfactant, and isopropyl alcohol as the cosurfactant evaluated for in vitro skin permeation through excised porcine skin. The in vitro skin permeation from these formulated microemulsions was sustained over 24 hours. The microemulsion F-8 (contained 10% of isopropyl myristate as oil phase, 8% of aqueous phase, and 82% of surfactant phase containing Tween 80 and isopropyl alcohol, 3 : 1) showed the highest permeation flux of 0.284 ± 0.003 μg/cm(2)/hour. All these microemulsions followed the Korsmeyer-Peppas model (R(2) = 0.971 to 0.998) with non-Fickian, \"anomalous\" mechanism over a period of 24 hours.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"428396"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/428396","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammed Maniruzzaman, Joshua S Boateng, Martin J Snowden, Dennis Douroumis
{"title":"A review of hot-melt extrusion: process technology to pharmaceutical products.","authors":"Mohammed Maniruzzaman, Joshua S Boateng, Martin J Snowden, Dennis Douroumis","doi":"10.5402/2012/436763","DOIUrl":"https://doi.org/10.5402/2012/436763","url":null,"abstract":"<p><p>Over the last three decades industrial adaptability has allowed hot-melt extrusion (HME) to gain wide acceptance and has already established its place in the broad spectrum of manufacturing operations and pharmaceutical research developments. HME has already been demonstrated as a robust, novel technique to make solid dispersions in order to provide time controlled, modified, extended, and targeted drug delivery resulting in improved bioavailability as well as taste masking of bitter active pharmaceutical ingredients (APIs). This paper reviews the innumerable benefits of HME, based on a holistic perspective of the equipment, processing technologies to the materials, novel formulation design and developments, and its varied applications in oral drug delivery systems.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"436763"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/436763","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9376769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Itraconazole Niosomes Drug Delivery System and Its Antimycotic Activity against Candida albicans.","authors":"Vijay D Wagh, Onkar J Deshmukh","doi":"10.5402/2012/653465","DOIUrl":"https://doi.org/10.5402/2012/653465","url":null,"abstract":"<p><p>Niosomes have potential applications in topical drug delivery system. The objective of the study was to formulate and evaluate the niosome of Itraconazole. Surfactant : cholesterol ratio and quantity of ethanol used were studied by applying factorial design. Formulated niosomes were evaluated for vesicle size, entrapment efficiency, drug release, skin permeation, and antimycotic activity. Vesicle size, entrapment efficiency, and drug release were markedly dependent on surfactant : cholesterol ratio and quantity of ethanol used. Permeation of the drug through the skin was affected by cholesterol content in formulation. Itraconazole niosome were having larger zone of inhibition than marketed formulation when activity was checked against C. albicans. Niosomes may be a promising carrier for topical delivery of Itraconazole especially due to their simple production.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"653465"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/653465","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9433096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kamiar Zomorodian, Mohammad Jamal Saharkhiz, Samaneh Shariati, Keyvan Pakshir, Mohammad Javad Rahimi, Reza Khashei
{"title":"Chemical Composition and Antimicrobial Activities of Essential Oils from Nepeta cataria L. against Common Causes of Food-Borne Infections.","authors":"Kamiar Zomorodian, Mohammad Jamal Saharkhiz, Samaneh Shariati, Keyvan Pakshir, Mohammad Javad Rahimi, Reza Khashei","doi":"10.5402/2012/591953","DOIUrl":"https://doi.org/10.5402/2012/591953","url":null,"abstract":"<p><p>Nepeta cataria L. is traditionally consumed as a food additive. The effects of three different harvest stages of N. cataria essential oils (EOs) against most common causes of food-borne infections were evaluated by broth microdilution method as recommended by the Clinical and Laboratory Standards Institute (CLSI). The chemical composition of the EOs from N. cataria has been analyzed by gas chromatography/mass spectrometry (GC/MS). The analysis of the EOs indicated that 4a-α,7-α,7a-β-nepetalactone (55-58%) and 4a-α,7-β,7a-α-nepetalactone (30-31.2%) were the major compounds of the EOs at all developmental stages. The results showed that the tested EOs exhibited antimicrobial activities against the food-borne pathogens at concentrations of 0.125-2 μL/mL. Based on these results, the EO of N. cataria can possibly be used in food products as a natural preservative agent.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"591953"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/591953","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of the immune system in nevirapine-induced subclinical liver injury of a rat model.","authors":"Zanelle Bekker, Andrew Walubo, Jan B du Plessis","doi":"10.5402/2012/932542","DOIUrl":"https://doi.org/10.5402/2012/932542","url":null,"abstract":"<p><p>In this study, the role of the immune system in nevirapine- (NVP-) induced subclinical liver injury was investigated by observing for changes of some immune parameters during the initial stages of NVP-induced hepatotoxicity in a rat model. In the acute phase, two test-groups of 10 Sprague-Dawley rats each were administered with bacterial lipopolysaccharide (LPS) or saline (S) intraperitoneally, followed by oral NVP, after which 5 rats from each group were sacrificed at 6 and 24 hours. For the chronic phase, two groups of 15 rats each received daily NVP, and on days 7, 14, and 21, five rats from each group were administered with either LPS or S, followed by that day's NVP dose, and were sacrificed 24 hours later. NVP caused liver injury up to seven days and progressively increased IL-2 and IFN-γ levels and lymphocyte count over the 21 days. NVP-induced liver injury was characterized by apoptosis and degeneration changes, while, for LPS, it was cell swelling, leukostasis, and portal inflammation. Coadministration of NVP and LPS attenuated NVP-induced liver injury. In conclusion, the immune system is involved in NVP toxicity, and the LPS effects may lay the clue to development of therapeutic strategies against NVP-induced hepatotoxicity.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"932542"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/932542","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ISRN PharmaceuticsPub Date : 2012-01-01Epub Date: 2012-09-04DOI: 10.5402/2012/364261
Amitava Roy, Kalpana Roy, Sarbani Roy, Jyotirmoy Deb, Amitava Ghosh, Kazi Asraf Ali
{"title":"Response surface optimization of sustained release metformin-hydrochloride matrix tablets: influence of some hydrophillic polymers on the release.","authors":"Amitava Roy, Kalpana Roy, Sarbani Roy, Jyotirmoy Deb, Amitava Ghosh, Kazi Asraf Ali","doi":"10.5402/2012/364261","DOIUrl":"10.5402/2012/364261","url":null,"abstract":"<p><p>The aim of the present work was designed to develop a model-sustained release matrix tablet formulation for Metformin hydrochloride using wet granulation technique. In the present study the formulation design was employed to statistically optimize different parameters of Metformin hydrochloride tablets at different drug-to-polymer ratios employing polymers Hydroxypropyl methylcellulose of two grades K4M and K100M as two independent variables whereas the dependent variables studied were X(60), X(120), T(50), T(90), n, and b values obtained from dissolution kinetics data. The in vitro drug release studies were carried out at simulated intestinal fluids, and the release showed a non-Fickian anomalous transport mechanism. The drug release was found to reveal zero order kinetics. The granules and the tablets were tested for their normal physical, morphological, and analytical parameters and were found to be within the satisfactory levels. There were no significant drug-polymer interactions as revealed by infrared spectra. It has been found out that on an optimum increased Hydroxypropyl methylcellulose K100M concentration and decreased Hydroxypropyl methylcellulose K4M concentration the formulations were elegant in terms of their release profiles and were found to be statistically significant and generable.</p>","PeriodicalId":14802,"journal":{"name":"ISRN Pharmaceutics","volume":"2012 ","pages":"364261"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9368122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}